These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Novel coronavirus SARS-CoV-2 (Covid-19) dynamics inside the human body. Saha A; Saha B Rev Med Virol; 2020 Sep; 30(5):e2140. PubMed ID: 32686248 [TBL] [Abstract][Full Text] [Related]
24. Epigenetic dysregulation of ACE2 and interferon-regulated genes might suggest increased COVID-19 susceptibility and severity in lupus patients. Sawalha AH; Zhao M; Coit P; Lu Q Clin Immunol; 2020 Jun; 215():108410. PubMed ID: 32276140 [TBL] [Abstract][Full Text] [Related]
25. Recombinant human ACE2: potential therapeutics of SARS-CoV-2 infection and its complication. Pang X; Cui Y; Zhu Y Acta Pharmacol Sin; 2020 Sep; 41(9):1255-1257. PubMed ID: 32581256 [No Abstract] [Full Text] [Related]
26. Computational Alanine Scanning and Structural Analysis of the SARS-CoV-2 Spike Protein/Angiotensin-Converting Enzyme 2 Complex. Laurini E; Marson D; Aulic S; Fermeglia M; Pricl S ACS Nano; 2020 Sep; 14(9):11821-11830. PubMed ID: 32833435 [TBL] [Abstract][Full Text] [Related]
27. JAK Inhibition as a New Treatment Strategy for Patients with COVID-19. Seif F; Aazami H; Khoshmirsafa M; Kamali M; Mohsenzadegan M; Pornour M; Mansouri D Int Arch Allergy Immunol; 2020; 181(6):467-475. PubMed ID: 32392562 [TBL] [Abstract][Full Text] [Related]
28. Advances in the use of chloroquine and hydroxychloroquine for the treatment of COVID-19. Sun J; Chen Y; Fan X; Wang X; Han Q; Liu Z Postgrad Med; 2020 Sep; 132(7):604-613. PubMed ID: 32496926 [TBL] [Abstract][Full Text] [Related]
29. Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity. Zhu Y; Yu D; Yan H; Chong H; He Y J Virol; 2020 Jul; 94(14):. PubMed ID: 32376627 [TBL] [Abstract][Full Text] [Related]
30. Interaction of SARS-CoV-2 and Other Coronavirus With ACE (Angiotensin-Converting Enzyme)-2 as Their Main Receptor: Therapeutic Implications. Davidson AM; Wysocki J; Batlle D Hypertension; 2020 Nov; 76(5):1339-1349. PubMed ID: 32851855 [TBL] [Abstract][Full Text] [Related]
31. The Anticoagulant Nafamostat Potently Inhibits SARS-CoV-2 S Protein-Mediated Fusion in a Cell Fusion Assay System and Viral Infection In Vitro in a Cell-Type-Dependent Manner. Yamamoto M; Kiso M; Sakai-Tagawa Y; Iwatsuki-Horimoto K; Imai M; Takeda M; Kinoshita N; Ohmagari N; Gohda J; Semba K; Matsuda Z; Kawaguchi Y; Kawaoka Y; Inoue JI Viruses; 2020 Jun; 12(6):. PubMed ID: 32532094 [TBL] [Abstract][Full Text] [Related]
32. SARS-CoV-2 and cardiovascular complications: From molecular mechanisms to pharmaceutical management. Wu L; O'Kane AM; Peng H; Bi Y; Motriuk-Smith D; Ren J Biochem Pharmacol; 2020 Aug; 178():114114. PubMed ID: 32579957 [TBL] [Abstract][Full Text] [Related]
33. Neurological injuries in COVID-19 patients: direct viral invasion or a bystander injury after infection of epithelial/endothelial cells. Azizi SA; Azizi SA J Neurovirol; 2020 Oct; 26(5):631-641. PubMed ID: 32876900 [TBL] [Abstract][Full Text] [Related]
34. Single-cell analysis of SARS-CoV-2 receptor ACE2 and spike protein priming expression of proteases in the human heart. Liu H; Gai S; Wang X; Zeng J; Sun C; Zhao Y; Zheng Z Cardiovasc Res; 2020 Aug; 116(10):1733-1741. PubMed ID: 32638018 [TBL] [Abstract][Full Text] [Related]
35. Coronavirus Disease 2019 and Stroke: Clinical Manifestations and Pathophysiological Insights. Divani AA; Andalib S; Di Napoli M; Lattanzi S; Hussain MS; Biller J; McCullough LD; Azarpazhooh MR; Seletska A; Mayer SA; Torbey M J Stroke Cerebrovasc Dis; 2020 Aug; 29(8):104941. PubMed ID: 32689643 [TBL] [Abstract][Full Text] [Related]
36. Virological and clinical cure in COVID-19 patients treated with hydroxychloroquine: A systematic review and meta-analysis. Sarma P; Kaur H; Kumar H; Mahendru D; Avti P; Bhattacharyya A; Prajapat M; Shekhar N; Kumar S; Singh R; Singh A; Dhibar DP; Prakash A; Medhi B J Med Virol; 2020 Jul; 92(7):776-785. PubMed ID: 32297988 [TBL] [Abstract][Full Text] [Related]
37. Sodium status and kidney involvement during COVID-19 infection. Post A; Dullaart RPF; Bakker SJL Virus Res; 2020 Sep; 286():198034. PubMed ID: 32445872 [TBL] [Abstract][Full Text] [Related]
38. H Yang G Am J Physiol Cell Physiol; 2020 Aug; 319(2):C244-C249. PubMed ID: 32515982 [TBL] [Abstract][Full Text] [Related]
39. Studies on viral pneumonia related to novel coronavirus SARS-CoV-2, SARS-CoV, and MERS-CoV: a literature review. Liya G; Yuguang W; Jian L; Huaiping Y; Xue H; Jianwei H; Jiaju M; Youran L; Chen M; Yiqing J APMIS; 2020 Jun; 128(6):423-432. PubMed ID: 32363707 [TBL] [Abstract][Full Text] [Related]
40. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), a newly emerged pathogen: an overview. Rathore JS; Ghosh C Pathog Dis; 2020 Aug; 78(6):. PubMed ID: 32840560 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]